Invigor Medical review: a compounding-forward clinic priced in vapor

The legal entity is Ikon Health LLC (DBA Try Invigor), at 3180 W Clearwater Ave, Ste G, Kennewick, WA 99336, per the terms and conditions. The about page says only that "TRY INVIGOR IS A MEDICAL CLINIC BASED IN WASHINGTON STATE AND OFFERS TELEMEDICINE SERVICES." No founding date is published. The older domain, invigormedical.com, dates to 2018; tryinvigor.com is new, and the company appears to have migrated to it within the last year.

Two people are named, and not on the about page. The editorial-process page lists "Dr. Hamilton, Medical Director" and "Stephen Jones, PA-C" as a clinical board member; a podcast page elsewhere on the site gives the medical director's full name as Dr. Andrew Hamilton. Neither has a state licence number, a licensure jurisdiction, or a bio detailed enough to check against a state medical board without guesswork. That's more disclosure than several direct competitors offer. It's also less than the reader needs.

Pick a product, fill in a questionnaire, wait for a licensed clinician to review it, get a video visit if the product requires one, then receive the medication in the mail from a partner pharmacy. The pharmacies page names five: Strive, Tailor Made, Belmar Pharma Solutions, Olympia, and GoGoMeds. For none of them does the page disclose a state, a licence number, or a 503A vs 503B designation. It is a carousel of logos.

That matters more than it sounds. A 503A pharmacy compounds patient-specific prescriptions one script at a time under state licensure. A 503B outsourcing facility manufactures in bulk under something closer to a pharmaceutical-grade quality system, with FDA registration and inspection. Two different regulatory regimes, two different quality bars — and a patient reading the site cannot tell which one is filling their vial.

Invigor's sitemap lists 26 treatment plans. Trimix is "$229 per Vial" with no volume specified and no strengths named. The TRT page doesn't name the ester. The four GLP-1 plans use only class labels — "GLP-1", "GLP-1/GIP", "micro-dose GLP-1" — and never say semaglutide or tirzepatide.

To their credit, each GLP-1 page carries the required compounding disclaimer verbatim: "Compounded drugs are not FDA-approved and don't undergo FDA review for safety, effectiveness, or manufacturing quality." That's the FDA's own language, and it belongs where Invigor put it.

The pricing is where the site starts to leak trust, and the leak is in the machine-readable layer rather than the visible one. The sermorelin plan page headlines "Starting At $220", and the longevity category page shows the same $220 next to it.

What a searcher sees is different. That longevity page's own meta description — the text Google prints under the link — reads "treatments like Sermorelin, which supports natural growth hormone production, At $125 a month". The $125 is the testosterone price further down the same page; the description staples it to sermorelin. And the vitality sub-page, where sermorelin injections are one of five listed treatments, publishes $185.50 in its structured data — a figure that appears nowhere on the visible page but does appear in Google's result. Three numbers for one product, depending on which surface you meet it on.

The homepage carries a "4.7 Average Rating" badge alongside "50 States Licensed", "35,000+ Happy Customers" and "1,000+ 5-Star Reviews". None of the four is footnoted or sourced. The 4.7 doesn't match the 4.4 on the company's Trustpilot profile. And the "50 States Licensed" claim runs straight into the B12 page, which states: "This product is not available for the state of California."

Here is where the regulatory environment collides with the product page.

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Once a drug leaves the shortage list, the legal basis for mass-compounding it under Section 503A collapses. The 503B wind-down for semaglutide expired 22 May 2025. On 30 April 2026 the agency proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, with public comment closing 29 June. And on 8 June 2026 the FDA's Office of Compounding Quality and Compliance issued 25 warning letters to telehealth companies over how compounded GLP-1s were being marketed — chiefly for implying FDA approval and for equating the compound to the branded drug.

A search of the FDA warning letter database for "Invigor Medical" comes up empty. That's a real negative result, not a clean bill of health: a letter aimed at a parent entity, a partner pharmacy or a different trade name wouldn't surface under that exact string.

What matters for a patient is this. Invigor is still selling compounded GLP-1s in an environment where the shortage-based pathway has closed and the FDA is actively issuing letters about how they are described. Invigor's own pages describe them only by class. A reader cannot tell from the buy button which molecule they are buying, at what dose, from which pharmacy, under which pathway.

The site advertises live video consultations with licensed clinicians, which is more than the async-only model some budget DTC clinics use, and the two named clinicians give the operation a public face. Beyond that, we could not find on any page a published follow-up cadence, a lab-monitoring schedule for peptide or TRT patients, a description of dose-adjustment protocols, or a written policy for handling adverse events. Some of that machinery may exist inside the patient portal after you pay. None of it is discoverable before you do.

A patient starting sermorelin or a GLP-1 needs to know how often they will be seen, what labs will be drawn and when, and what happens if a side effect emerges at week six. On the public site, those answers are absent.

Five partner pharmacies, no 503A/503B labels, no state disclosures. A patient who wants to verify the pharmacy filling their prescription — check its inspection history, look up its state licence, read any FDA-483 observations against it — has to first find out which one shipped their order, which is not information any plan page provides.

For sterile injectables in particular, that opacity is the piece we would most want closed. A GLP-1 vial or a sermorelin injection is a sterile-compounded product. Sterility failures at compounding pharmacies are the source of the most serious historical harms in this category — the 2012 New England Compounding Center meningitis outbreak killed 64 people and started with a 503A operator that had drifted into de-facto manufacturing. This is exactly the risk 503B registration was designed to catch. A clinic that names its pharmacies without naming their regulatory status has done half the disclosure.

Beyond the GLP-1s, the catalogue sits in a patchwork. Sermorelin is compounded under 503A or 503B pathways, with the specific status varying by pharmacy. PT-141 (bremelanotide) exists as an FDA-approved product, Vyleesi, for one narrow indication — every other use, including anything Invigor prescribes it for, is off-label and typically compounded. NAD+, glutathione, oxytocin and methylene blue are compounded and used off-label for wellness indications the FDA has not evaluated.

That patchwork moved in July, and not in the direction most people expected. The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider seven peptides for the 503A bulk drug substances list. FDA's own reviewers had proposed rejecting all seven. The committee voted the other way on six of them; only emideltide was turned down. We logged every tally against the timestamps in FDA's own broadcast in our account of the vote.

Two things follow, and they pull against each other. A committee recommendation is not a rule — FDA has not adopted it, so nothing has actually changed in law. But the pressure a clinic like Invigor was under a year ago has eased rather than tightened. Sermorelin, worth noting, was not among the seven; its position was neither improved nor worsened by the vote.

The Trustpilot profile the brand's rating badge trades on is filed under invigormedical.com, the domain the company has largely moved off. Tryinvigor.com has no Trustpilot profile at all — the URL returns a 404, which we confirmed on 6 September 2026.

That legacy profile shows 4.4 out of 5 from 1,783 reviews, claimed March 2019, 81% five-star and 10% one-star. Only 25 of the 1,783 are from the last twelve months. The bulk of the score was earned years ago, on a domain most new patients will never visit.

One line on that page carries more weight than the score: Trustpilot records that Invigor Medical "Hasn't replied to negative reviews." For comparison, two other providers in this catalogue reply to 93% and 100% of theirs. It is a paid Trustpilot profile, so the silence isn't a question of access.

The compounding disclaimer is there on the GLP-1 pages. That is the one piece the FDA requires, and it is present. What is not: the molecule name on any GLP-1 page; the dose on any plan page; the pharmacy filling any particular script; the 503A vs 503B status of any partner pharmacy; any clinical evidence summary for the compounded peptides where the evidence base is thin; any mention of the FDA enforcement environment for compounded GLP-1s.

The terms are their own artifact. A Washington entity at a Washington address contracts under California law and arbitrates in Los Angeles — with a carve-out letting a patient more than 100 miles away arbitrate near home — under a capitalised class-action waiver. The terms also state that Try Invigor and its medical groups "are not enrolled with, and are not participating providers with, any federal or state healthcare programs (i.e., Medicare, Medicaid)". None of that is unusual for DTC telehealth. It does mean a patient with a complaint has fewer procedural options than the Washington address might suggest.

Invigor Medical is a real clinic with named clinicians, a named pharmacy chain, and a compounding disclaimer where the FDA requires one. On the disclosure dimensions that matter most to a patient making a decision — what molecule is in the vial, what dose, who compounded it, under which regulatory pathway, at what actual price — the site doesn't answer the questions.

The 4.7 badge that doesn't match the 4.4 rating. The sermorelin price that changes between the page, its own meta description and its own structured data. The 50-state claim contradicted by their own B12 page carving out California. The product called "micro-dose GLP-1" that never tells you the dose. And a review profile on an abandoned domain where nobody has answered a negative review. These are not clinical failures. They're trust failures, and they compound.

For someone considering compounded peptides or a GLP-1 through DTC telehealth in the current enforcement environment, the questions worth answering before signing up are exactly the ones this site doesn't answer.

Editorial note: This page is for informational purposes and doesn't constitute medical advice. Peptide therapy and GLP-1 decisions should be made with a licensed healthcare provider familiar with your medical history.